RNS Number : 8093B
15 January 2018
('e-Therapeutics' or the 'Company')
e-Therapeutics to collaborate with Intellegens and Biorelate
to enhance and extend its AI technology capabilities
Oxford, UK, 15 January 2018: e-Therapeutics, a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, today announces agreements with Intellegens and Biorelate. Both companies have artificial intelligence (AI) tools which, after pilot studies, have been proven to enhance ETX's existing computational NDD technology. No financial details were disclosed.
Intellegens is a spin-out from the University of Cambridge that has developed a unique AI method for training neural networks from incomplete data. The collaboration will allow e-Therapeutics to apply Intellegens' technology to the predication and error correction of large-scale biological and chemical data. This will enable neural networks to be trained on the sparse data typical of biological and chemical problems. Application of the technology will result in the enhancement of e-Therapeutics' existing proprietary databases facilitating greater coverage of chemical space. In addition, it will be used to develop a novel computationally guided approach to medicinal chemistry.
Manchester-based Biorelate provides biomedical knowledge by using AI to create curated databases from the analysis of published literature. Its cutting edge technology uniquely combines natural language processing (NLP) and machine learning with human expert curation. The result is the extraction of structured biological knowledge from the wide body of expert journals. The aim of the collaboration is to directly feed this knowledge into e-Therapeutics' Network-Driven Drug Discovery engine facilitating the pursuit of novel disease mechanisms.
Dr Jonny Wray, Head of Discovery Informatics at e-Therapeutics said "I'm excited we're entering into partnership with these two companies. We already utilize machine learning heavily in our discovery platform to augment empirical biological and chemical data. These partnerships will enhance and extend our internal capabilities via collaborations with companies at the cutting edge of AI research and application."
Dr Gareth Conduit, founder of Intellegens, said: "We are very excited to be entering into this relationship with e-Therapeutics. We believe our novel deep learning technology, specifically suited to sparse data problems, will significantly improve the data and enable more opportunities to be investigated within e-Therapeutics' Network-Driven Drug Discovery approach"
Dr Daniel G Jamieson, founder & CEO of Biorelate, said: "The partnership with e-Therapeutics is an important milestone in our on-going mission to curate truths in biomedicine. We will be supporting e-Therapeutics' drive to better understand how complex diseases work. As biomedical knowledge continues to expand, the need to harness this and better understand what is already known is now greater than ever."
For further information, please contact:
Ray Barlow, CEO
Jonny Wray, Head of Discovery Informatics
Tel: +44 (0) 1993 883 125
Melanie Toyne Sewell/Alex Shaw
Tel: +44 (0) 207 457 2020
Email: [email protected]
Notes to Editors
About e-Therapeutics plc
e-Therapeutics is an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.
Its novel methodology and Discovery Engine allow the Company to discover new and better drugs in a more efficient and effective way.
For more information about the Company, please visit www.etherapeutics.co.uk
Intellegens is a spin-out from the University of Cambridge that has developed a unique Artificial Intelligence method for training neural networks from incomplete data.
The technique, developed in the Department of Physics, has been applied to drug discovery and material design, but as the technique is generic it can be applied to many domains where there is big, incomplete data.
Biorelate is a venture-backed AI start-up, based in Manchester, UK, with a mission to curate truths in biomedicine.
By providing scientists with the necessary components to tackle biomedicine's biggest unanswered questions they aim to propel life sciences research into a new era of big data analysis.
This information is provided by RNS
The company news service from the London Stock Exchange